**Only for Pharma People** 

# Oual Plane 3, Issue 12 December 2020, 30/-

The Learning and Development Journal

Patent
Opposition
in India

OXFORD Technology

VACCINE UPDATE

A Macro Insight to Micronutrient METHYLCOBALAMIN

Management of co-infection of COVID-

19 with other seasonal epidemic prone diseases

Dilly dallying in notifying

## METHYLCOBALAN

lays bare red tapism in key apex Institutions like FSSAI and ICMR

Learn to Cha Change to Suc

CORONA VACCINE RACE

# SHINDE JAGANNATH SAKHARAM

Chairman – MSCDA LTD , AIOCD LTD & President of The Maharashtra State Chemist & Drug Association








### Into Soft, Supple and Glowing Skin







## "The Aspiring venture for the benefit of all"

For further information, please write to:



7, Om Complex, Near Swastik cross roads, C G Road, Ahmedabad-380009 Gujarat, India. Phone: +91-79-40033144 Customer Care: +91-98795 33315 Email: info@asprius.in, medical@asprius.in, URL: www.asprius.in



Editor É in É chief Ms Anshu Yadav Senior Copy Editor Ms Ragini Arya Editor Dr. Sanjay Agrawal Consulting Editor M.D Parasha Image Designer Amaresh K A -Cube Graphics

#### Advisory Board

Dr Sanjay Agrawal Mr. Shiven Yadav Dr Avinash Shankar Mr Jagdev Singh Mr Subhash Chandra Ms Sudha Agrawal Ms Anaisha Singh Ms Shanvika Singh

Design & Publications
QualPharma -International

#### **ADDRESS**

INDIAN OFFICE

Jaipur -167, Pratap Nagar, Khatipura Road, Jaipur, Rajasthan-302021 # +91 9821104101, 9958855039

Ahemdabad 7, Om Complex, Near Swastik Cross Roads,CG Road,Ahmedabad, Gujarat 380009 # +91 9821104101, 9958855039 INTERNATIONAL OFFICE

Denmark Dr. Janne Harild, Skovduevej 23 3120 Droningmoelle **Denmark** 

Write to us @

qualpharmainternational@gmail.com

#### DISCLAIMER:

Readers are requested to verify and make appropriate enquiries to satisfy themselves about the veracity of the advertisement before responding. The Publisher, Printer and Editor of the magazine, does not vouch for the authenticity of any advertisement or advertiser or h q t " c p { " c f x g t v k u g t ø u " r event can the Publisher , Printer and Editor of this magazine be held responsible/liable in any manner whatsoever for any claims and /or damage for advertisement in this magazine.

Authors will be solely responsible for any issues arising due to copyright infringement and authenticity of the facts and figures mentioned in their article. QualPharma is not liable for any damages/ copyrights infringements.

No part of this publication can be reproduced or published in any form, without prior permission in writing from the publisher.

### FROM THE DESK OF EDITOR - IN – CHIEF

Dear Readers,

There has been lot of confusion like whether Methylco-balamin is banned or approved, what is the per usage serving value of the product etc. Methylcobalamin is widely marketed in the country as a drug for chronic neurological disorders with a recommended dietary allowance of 2000 mcg intramuscular but as per FSSAI it is detrimental for patients when used above 1 mcg for prevention and disease management.

At present there is no clarity on tolerable upper limit (TUL) along with confusion on RDA value of methylcobalamin. This is all the more contradictory considering that ICMR and National Institute of Nutrition (NIN) have recently issued another report which have different stipulated RDA values of methylcobalamin and estimated average nutrient requirements for Indians. QualPharma fully endorse that the RDA and per usage entity must be separated entity for nutraceuticals and FSSAI should review it technically.

Coming back to our edition we have SHINDE JAGAN-NATH SAKHARAM Chairman 6 MSCDA LTD, AIOCD LTD & President 6 The Maharashtra State Chem & Drug Association (p16) on our cover page and profile of Mr RAJIV SINGHAL General Secretary of AIOCD (p18). You may keep yourself updated on Corona stories, medical and marketing articles and zodiac prediction from our expert.

You may know more about us through <a href="http://www.qualpharma.in/">http://www.qualpharma.in/</a>. STAY UPDATED STAY BLESSED and do not forget to follow up our blog https://qual-pharma.blogspot.in/ to receive regular interesting updates.

(ANSHU YADAV)

# December Contents

9

#### QA/REGULATORY

Dilly dallying in notifying METHYLCOBALAMIN 5 lays bare red tapism in key apex institutions like FSSAI and ICMR

#### **MEDICAL**

A Macro Insight to a Micronutrient METHYLCOBALAMIN

#### **PERSONALITIES**

SHINDE JAGANNATH SAKHARAM—Chairman 6MSCDA LTD , AIOCD LTD & President 6The Maharashtra State Chemist and Drug Association


RAJIV SINGHAL—General Secretary of AIOCD 16

#### HEALTH AND WELLNESS

Management of co-infection of COVID-19 with other seasonal epidemic prone diseases

#### **MARKETING**

Learn to Change, Change to Succeed 24





#### PATENT AND TRADEMARK

Patent Opposition in India	27
CORONAVIRUS SPECIAL	
Corona Vaccine Race	32
OXFORD TECHNOLOGY	35
Two Vaccines by February in India	36
VACCINES UPDATE	36
No to Remdesivir for <b>COVID</b> advices WHO	37
Covaxin Technology	37
Research says Covid patients are infectious for first nine days from onset of infection	37

### <u>NEWS REVIEW</u>S

PM Modi Warns Of Possible Side-Effects 41

Ayurvedic doctor's authorized to do surgery 41

ZODIAC PREDICTION

43

### Dilly dallying in notifying METHYLCOBALAMIN lays bare red tapism in key apex institutions like FSSAI and ICMR

#### Our Fight Continues

Omission of key micronutrients like me- tation has been made to Union Ministry of thylcobalamin in Food Safety and Stan-Chemicals and Fertilizer. The consultants dards Authority of India (FSSAI) health have once again recommended DCGI to e supplement regulations 2016 as well as tiggiven the sole authority for implementat on ongoing methylcobalamin ban have not of nutraceutical policies and regulations, only led to a chaotic scene in the industryiting FSSAI as a toothless body. Ten ye but also laid bare redapism of key institu- ago, nutraceutical was under DCGI itself. tions like the Food Safety and Standards

Authority of India (FSSAI) and the Indian Nutraceutical and drug consultants have Council of Medical Research (ICMR), so alleged that FSSAI has been turning a blind much so that the pharma experts have outye to the contentious issues raised wi rightly defied the ban and asked for claritive ference to RDA values of Vitamin C and 2005. He is Editor-in-Chief of renowned from the Union Health Ministry, Union other micronutrients like methylcobalamin, Ministry of Chemicals and Fertilizers &which are vital for boosting immunity, men Drugs Controller General of India (DCGI). tal health and other coorbid chronic ailments in the crucial juncture of COVID9

Both FSSAI and ICMR have been adamant pandemic.

in their approach wherein FSSAI has not

responded responsibly as yet on the kellprime Minister Narendra Modi has recomissue of revoking the ban on methylcobalamended 1000 mg of Vitamin C for prophy lactic use against COVID 9 whereas its min.

However, under the current premise andnterventions by apex and responsible au-formulations. having bore the brunt of the insensible bethorities like ICMR, FSSAI and DCGI. havior of the authorities, a recent represen-



Dr Sanjay Agrawal

Dr Agrawal has actively worked in pharmaceutical and related industries for more than 35 years and started this firm Pharmaceutical Consultants and Inventor in IJM Today . Dr Sanjay Agrawal is the illustrious member of the National Geographic Society and ex-member of scientific committee of IDMA. He had received various awards for his valuable support and contributions in Healthcare and pharmaceutical sector Dr. Agrawal obtained his postgraduation in Biochemistry from prestigious institution. He has worked with many International and national Pharmaceuticals companies. Dr. Sanjay Agrawal RDA is suggested as only 40 mg due to po(is the patent holder of atleast 40 research

#### **QA & REGULATORY**

Methylcobalamin is an essential nutrientand food safety officers to launch surveiproved, there is no value of prescribing and is required to treat vitamin B12 defilance drives against various brands of RDA value for the same. Surprisingly the ciency in people with pernicious anaemia, products containing methylcobalamin mails which we have received from FSSAI diabetes and other conditions as well. It ibeing manufactured and sold under mention the same RDA for both methylimportant for the brain, nerves and for FSSAI license. cobalamin and cyanocobalamin. It is the production of red blood cells (RBCs). noteworthy that here the discussion is Since, source of methylcobalamin is fromOn the other hand Former CEO of FSSAI about 'per serving' usage value which the non-vegetarian products hence supple-Pawan Agrawal had promised in Decem-manufacturer can refer to and not the mentation with methylcobalamin be-ber 2019 that methylcobalamin has beenRDA value for a healthy person. comes very essential, specially for Indi-approved by their scientific committee ans. Therefore, when a supplement isand in due course of time will be included present there is also no clarity on tolertaken prophylactically, it must at least ben the gazette. But it's been almost a yeable upper limit (TUL) along with confuof the therapeutic dose. without any progress regarding the inclusion on RDA value of methylcobalamin. sion of methylcobalamin in the gazette. This is all the more contradictory consid-There has been lot of confusion like ering that ICMR and National Institute of whether Methylcobalamin is banned or On January 7, 2020, FSSAI issued a noti-Nutrition (NIN) has recently issued anapproved, what is the per usage servingication regarding RDA of vitamin B12 other report which has different stipuvalue of the product etc. Methylcobalawherein it was mentioned as 1 mcg withated RDA values of methylcobalamin and min is widely marketed in the country asout mentioning which type of vitamin B12estimated average nutrient requirements a drug for chronic neurological disorderslike methylcobalamin, adenosylcobala- for Indians. with a recommended dietary allowancemin, hydroxycobalamin or cyanocobala-(RDA) of 2000 mcg intramuscular but asmin. It is wellknown that Vitamin B12 is preper FSSAI it is detrimental for patients sent majorly in norvegetarian sources. when used above 1 mcg for prevention he dual standards of FSSAI can also beHere it is noteworthy that in a country and disease management. seen by the presence of already FSSAsuch as US wherein major population approved brands available with 1500 mcconsume nonvegetarian products, the Gujarat FDCA Commissioner, Dr H G gty/per serving. Rejunex CD3 of Intas is &DA for methylcobalamin is 2.4 mcg Koshia, has been quoted as saying that SSAI approved product containing 1500 whereas, in India, most of the population there is a ban on methylcobalamin pan mcg methylcobalamin. Some of the consumes vegetarian diet, but the RDA India and the states need to follow it assidely sold brands are Locopen capset is a mere 1 mcg. per FSSAI directive. The Central Drugs sule, Neugaba M 75 capsule, Nervup Standard Control Organisation (CDSCO) 500 mcg injection, Nuroz Forte, According to industry person Anshu had urged the FSSAI to take actionNurofine -2500 injection, Actavis

According to industry person Anshu MUXUjž [=h ] g bck Uad m issue about taking action on methylcobalamin manufacturers is totally uncalled for. Reason being that the letter issued by FSSAI deputy director to Gujarat state

of the same, it has been recommended orbintil and unless FSSAI does not inform drug control department to take action on priority basis to instruct drug inspectorshe industry that methylcobalamin is ap-methylcobalamin manufacturers without

against Gujaratbased manufacturers for 2500 injection, etc. There are more

manufacture and sale of methylcobalamin than half a dozen other brands with

meant for the rapeutic intervention which the same formula.

is in contravention of the norms. In view

#### **QA & REGULATORY**

any intimation to the then FSSAI CEO medical condition. It is pertinent thattry that methylcobalamin is approved, Pawan Kumar Agarwal indicating lobby- other countries have kept RDA and 'perthere is no value of prescribing RDA value ing and malafide intent to discourageserving' usage value as separate entities for the same."

] b X i g h f m  $^\circ$  U b X  $^\circ$  h c  $^\circ$  g U h ]  $\overline{g}$ h $\overline{u}$ s no on be  $\overline{u}$  by  $\overline{u}$ 

by FSSAI in India.

We as stakeholders of pharma fraternity have appealed to the Centre to delegate

Pharma experts have also voiced concerns

that when methylcobalamin has been "There is an urgent need for inclusion of the responsibility of nutraceutical diviapproved by CDSCO up to 2000 mcg themsethylcobalamin in the gazette and re-sion to the DCGI in our recent representation which is of no use. DCGI has approveducts, by not forgetting that products are and Fertilizers. Ten years back 2,000 mcg of methylcobalamin even in already available at higher concentra-nutraceutical was under DCGI only. Injectable form and respective brands aretions", informs pharma expert Anshu available as physicians recommend me- Yadav. She further adds, "that until and "By Dr Sanjay Agrawal thylcobalamin based on the patient's unless FSSAI does not inform the indus-

# With Best Complements





NAAZCOLD Enjoy Life with Anticold Aspivit-369
Capsule / Symp
Step towards better health

Asprius Lifesciences - C G Road, Ahmedabad-380009 Email: info@asprius.in, medical@asprius.in URL: www.asprius.in

© Registered Fademark of Aspitus Literaturous

# **Attention!**

### **Pharma Marketers**

# Develop a competitive edge with Patented products

# Innovative solutions available for sale or collaboration

- HEPATITIS
- . FATTY LIVER (TWO)
- BILIARY AND RENAL COLIC
- ANDROPAUSE
- THALASSEMIA
- LIVER DISORDER
- THROAT INFECTION









DOMI UP









LEADING PHARMA CONSULTANT AND INVENTOR CONTACT US AT

WEBSITE: http://drsanjayagrawal.in/ EMAIL ID:drsanjay@drsanjayagrawal.in

PHONE: 91-9825381729

# QualPharma

#### MONTHLY MAGAZINE

## ADVERTISEMENT RATE CARD

### Make your presence in Pharma World

POSITIONS			
Size	Monthly	Annually	
Full size A4 page Full size A4 page [Spread]	5,000/-	30000/-	
2/3 Page	4,500/-	27000/-	
½ size A4 page [Horizontal/Vertical]	3,000/-	18000/-	
1/4 size A4 page	2,000/-	12000/-	
Back side cover Back Inside cover Front inside cover	10,000/-	60000/-	
Foot band	750/-	5500/-	

Material Required: High resolution Soft copy in JPEG/PDF with colour proofs to be supplied by the advertiser.

#### MECHANICAL DATA

Size	Horizontal	Vertical
Full size A4 page	, " ) Î	%%Î
2/3 Page	, ") Î	+ " & ) Î
1/2 size A4 page [Horizontal]	, ") Î	) " ) Î
½ size A4 page [Vertical]	( " & ) Î	%%Î
1/4 size A4 page	( " & ) Î	) " ) Î
Foot band	, ")Î#&"	+ ) Î' " & ) Î # %%ĺ

Rngcug "gpnkuv" o { "uwduetkrvkqp "htqoíííííííóo 0 0 "vq "ííííííííííí

**Bank Details** 

Account Name - Anshu Yadav

Bank Address - THE RATNAKAR BANK LTD, PITAMPURA, Delhi

Account Number - 309958855039 IFSC Code - RATN0000190

Online transaction is acceptable at this ID.

Note: Please intimate at qualpharmainternational@gmail.com post payment.

91-9958855039

Only for Pharma People

# Qual Pharma

The Learning and Development Journal





























# ADDRESS INDIAN OFFICE Jaipur

167, Pratap Nagar, Khatipura Road, Jaipur, Rajasthan - 302021 # +91 9821104101, 9958855039

#### Ahemdabad

7, Om Complex, Near Swastik Cross Roads, CG Road, Ahmedabad, Gujarat - 380009 # +91 9821104101, 9958855039

#### INTERNATIONAL OFFICE

#### Denmark

Dr. Janne Harild Skovduevej 23 3120 Droningmoelle Denmark

http://www.qualpharma.com